CN101396350A - Clopidogrel hydrogen sulfate dispersible tablets and preparation method thereof - Google Patents
Clopidogrel hydrogen sulfate dispersible tablets and preparation method thereof Download PDFInfo
- Publication number
- CN101396350A CN101396350A CNA2008102169856A CN200810216985A CN101396350A CN 101396350 A CN101396350 A CN 101396350A CN A2008102169856 A CNA2008102169856 A CN A2008102169856A CN 200810216985 A CN200810216985 A CN 200810216985A CN 101396350 A CN101396350 A CN 101396350A
- Authority
- CN
- China
- Prior art keywords
- hydrogen sulfate
- clopidogrel hydrogen
- preparation
- clopidogrel
- dispersible tablets
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an anti-platelet aggregation drug-clopidogrel hydrogen sulfate tablet dispersible tablet and a preparation method thereof. The clopidogrel hydrogen sulfate tablet dispersible tablet consists of 30 percent to 55 percent of clopidogrel hydrogen sulfate and 45 percent to 70 percent of auxiliary materials according to the weight percentage. The auxiliary materials comprise disintegrant, loading agent, lubricant and taste-modifying agent, wherein, the disintegrant accounts for 5 percent to 20 percent of the total weight percentage of the prescription. The preparation method of the clopidogrel hydrogen sulfate tablet dispersible tablet is wet granulation tabletting press method or direct powder pressing method. Compared with other forms of preparation, the invention has the advantages of good dispersing state, short disintegration time, fast drug dissolvability, convenient drug administration, low production cost, good portability, high stability, etc.
Description
Technical field
The present invention relates to a kind of platelet aggregation inhibitor clopidogrel hydrogen sulfate dispersible tablets and preparation method thereof.
Background technology
Clopidogrel is as the antiplatelet drug of a new generation, in liver, become active metabolite through the Cytochrome P450 biotransformation, optionally suppress adenosine diphosphate (ADP) (ADP) and its combining and the activation of the glycoprotein GP II b/III a complex of the ADP of secondary mediation of platelet receptor, thereby suppress hematoblastic gathering.Be used for the treatment of restenosis and thrombotic complications etc. in atheromatosis, acute coronary artery syndrome, the prevention intracoronary stent implantation after-poppet clinically.
Chlorine pyrroles thunder is with the form administration of disulfate, and disclosed at present chlorine pyrroles thunder preparation has tablet, capsule, drop pill, injection.Do not see the pertinent literature report of clopidogrel hydrogen sulfate dispersible tablets as yet.Chlorine pyrroles thunder is almost insoluble in neutral water, and easily forms the bigger insoluble aggregate of viscosity after meeting water, so its solid preparation easily causes content inhomogeneous when wetting agent carries out wet granulation using water as.Also exist chlorine pyrroles thunder to be degraded to the problem of chlorine pyrroles fulminic acid in addition.Point out among the patent US6914141 that magnesium stearate lubricant can cause the degraded of bisulfate clopidogrel with clopidogrel generation interaction.Chinese patent CN200610063151.7 discloses solid preparation of a kind of chlorine pyrroles thunder sulfate and preparation method thereof, use glycerol Palmic acid stearate to solve the problem that chlorine pyrroles thunder is degraded to chlorine pyrroles fulminic acid in the component, but effect is not satisfactory as lubricant.Compressing dry granulation is adopted in the preparation of its tablet, for medicine is mixed fully, added a large amount of adjuvants and finally made the tablet that specification is 25mg by very complicated technology, this can increase drug manufacture cost and cycle undoubtedly, chlorine pyrroles thunder sheet conventional taking dose clinically is 75mg/ time in addition, be equivalent to 25mg specification tablet and need once take three, obviously be unfavorable for improving patient's compliance.Conventional tablet is often because of disintegrate and the slow abundant absorption that influences medicine of stripping in the existing dosage form; Though liquid preparation absorbs fast, need injection, use is inconvenient, and poor stability, packing, transportation is stored equal inconvenient.Therefore be necessary to develop a kind of novel chlorine pyrroles thunder preparation.
Summary of the invention
The purpose of this invention is to provide a kind of clopidogrel hydrogen sulfate dispersible tablets and preparation method thereof, it is reasonable that it has component, technology is simple, disintegration time is short, the medicine stripping rapidly, absorb fast and can improve the characteristics of drug bioavailability, also make old man, the difficult patient that swallows and taking medicine in water-stressed conditions become more convenient simultaneously.
For achieving the above object, the present invention adopts following technical scheme:
A kind of clopidogrel hydrogen sulfate dispersible tablets, contain following component by weight percentage:
Clopidogrel hydrogen sulfate 30～55%
The adjuvant surplus.
Preferably:
Clopidogrel hydrogen sulfate 35～45%
Adjuvant 55～65%
Wherein, described adjuvant comprises disintegrating agent, filler, lubricant, correctives.
Disintegrating agent is selected from one or both the mixture in low-substituted hydroxypropyl cellulose, the cross-linking sodium carboxymethyl cellulose, and accounting for total weight percent is 5～20%.Add in when disintegrating agent can mix or add during tabletting or inside and outsidely all add.
Filler is selected from one or more the mixture in lactose, mannitol, microcrystalline Cellulose, the pregelatinized Starch, and accounting for total weight percent is 25～60%.
Lubricant is selected from one or both the mixture in stearic acid, castor oil hydrogenated, the micropowder silica gel, and accounting for total weight percent is 1～5%.
The preparation method of clopidogrel hydrogen sulfate dispersible tablets can be direct powder compression and wet granulation process.
1, direct powder compression: with tabletting behind bisulfate clopidogrel and filler, disintegrating agent, lubricant and the sweeting agent mix homogeneously.
2, wet granule compression tablet method: bisulfate clopidogrel and filler are mixed, do not add or add part or all of disintegrating agent, correctives mixing, add binding agent and make soft material, granulate 40～50 ℃ of oven dry, granulate, add in addition part or all of disintegrating agent, add the lubricant mixing again, tabletting.Wherein binding agent adopts a kind of in the alcoholic solution of hydroxypropyl emthylcellulose or tween 80 or their mixture.
In the preparation of described clopidogrel hydrogen sulfate dispersible tablets, raw material, adjuvant all needed 80 mesh sieves.
Preparation technology's preferred version is: raw material and other adjuvants crossed 80 mesh sieves respectively, takes by weighing clopidogrel hydrogen sulfate, filler, disintegrating agent, lubricant and sweeting agent, mix the back after 80 mesh sieves twice by the equivalent incremental method by group component, and tabletting, promptly.
In the experimental study process, the present invention has carried out investigating checking respectively to the preparation technology of wet granule compression tablet and direct powder compression.The result is presented in the wet-granulation process clopidogrel hydrogen sulfate and meets and promptly be clamminess behind the water and can produce aggregation, adopts binder aqueous solution to granulate easily to cause the tablet content of being suppressed inhomogeneous, and correspondingly, the dissolution homogeneity is also relatively poor.Find in the experimentation that when using ethanol instead and making wetting agent, the viscosity of medicine wet granular obviously reduces, pelletization is easier to relatively.For the dissolubility that improves medicine and help molding particles, the present invention adopts the alcoholic solution of hydroxypropyl emthylcellulose or tween 80 to make binding agent, the dispersing uniformity of chlorine pyrroles thunder dispersible tablet and dissolution all be improved significantly.Adopt the technology of direct powder compression comparatively simple, solvent contact not in preparation process also need not heating, has therefore correspondingly improved stability of formulation.But direct powder compression is had relatively high expectations to the flowability of adjuvant, need reach certain fluidity after supplementary material mixes and just can not cause bigger tablet weight variation.
Disintegration rate is the key parameter of dispersible tablet, so the selection of disintegrating agent is extremely important.The present invention has carried out great deal of experimental to the kind and the consumption of disintegrating agent in the component.On the technical foundation of existing bibliographical information, carboxymethyl starch sodium, low substituted hydroxy-propyl methylcellulose, several disintegrating agents of cross-linking sodium carboxymethyl cellulose have been investigated respectively.The result shows, for after the disintegrating agent tabletting places a period of time, tablet can turn to be yellow with the carboxymethyl starch sodium.Study on Compatibility by supplementary material is found, with chlorine pyrroles thunder and carboxymethyl starch sodium powder mixes put place ten days under influence factor's condition after, powder can be become brown by original white, and with the most obvious under the hot conditions, so disintegrating agent carboxymethyl base Starch Sodium is got rid of.Through repetition test, determine that finally preferred disintegrating agent is one or both or the mixture in low-substituted hydroxypropyl cellulose, the cross-linking sodium carboxymethyl cellulose, accounting for total weight percent is 5～20%.And when the percentage ratio consumption of disintegrating agent is controlled in 7～15% scopes, the dispersing uniformity of its dispersible tablet and dissolution the best.
In addition, there is document to show that the clopidogrel hydrogen sulfate preparation can produce the problem of chlorine pyrroles thunder degraded when using magnesium stearate to make lubricant.Therefore, the present invention has also made Preliminary screening to the use of lubricant, respectively stearic acid, fumaric acid sodium stearate, three kinds of lubricants of castor oil hydrogenated is investigated.Find that in the compatibility test of supplementary material the fumaric acid sodium stearate uses the problem that the degraded variable color can occur with clopidogrel hydrogen sulfate.And stearic acid, castor oil hydrogenated and clopidogrel hydrogen sulfate compatibility are more stable after using, and significant change does not all take place characters powder, and its preparation is all up to specification through content and determination of related substances.
In sum, good effect of the present invention is, disintegrating agent kind and consumption are being carried out on the basis of screening and optimizing, technology by comparatively simple directly pressed powder or wet granule compression tablet is made stable clopidogrel hydrogen sulfate dispersible tablets, its production technology does not need special installation, production cost is lower, and compares with conventional tablet, has more superior disintegrate and dissolving out capability.
The present invention is further detailed explanation below in conjunction with the specific embodiment.
The specific embodiment
The specification of clopidogrel hydrogen sulfate dispersible tablets is 75mg/ sheet (calculating with chlorine pyrroles thunder) in following examples component.
(sheet is heavy: 220mg) in the preparation of embodiment 1 clopidogrel hydrogen sulfate dispersible tablets
Preparation method: bisulfate clopidogrel, lactose, microcrystalline Cellulose, low-substituted hydroxypropyl cellulose, micropowder silica gel, correctives and the stearic acid of getting group component are crossed 80 mesh sieve mix homogeneously, and direct powder compression promptly.
(sheet is heavy: 250mg) in the preparation of embodiment 2 clopidogrel hydrogen sulfate dispersible tablets
Preparation method: bisulfate clopidogrel, lactose, microcrystalline Cellulose, cross-linking sodium carboxymethyl cellulose, micropowder silica gel, correctives and the castor oil hydrogenated of getting group component are crossed 80 mesh sieve mix homogeneously, and direct powder compression promptly.
(sheet is heavy: 280mg) in the preparation of embodiment 3 clopidogrel hydrogen sulfate dispersible tablets
Preparation method: bisulfate clopidogrel, lactose, microcrystalline Cellulose, low-substituted hydroxypropyl cellulose, cross-linking sodium carboxymethyl cellulose, micropowder silica gel, correctives and the stearic acid of getting group component are crossed 80 mesh sieve mix homogeneously, and direct powder compression promptly.
(sheet is heavy: 180mg) in the preparation of embodiment 4 clopidogrel hydrogen sulfate dispersible tablets
Preparation method: bisulfate clopidogrel, lactose, microcrystalline Cellulose, low-substituted hydroxypropyl cellulose, the correctives mixing of getting group component, add an amount of 5%HPMC alcoholic solution system soft material, 30 mesh sieves are granulated, 40 ℃ of oven dry, 20 mesh sieve granulate add stearic acid, mixing, tabletting promptly gets the bisulfate clopidogrel sheet.
(sheet is heavy: 220mg) in the preparation of embodiment 5 clopidogrel hydrogen sulfate dispersible tablets
Preparation method: bisulfate clopidogrel, lactose, pregelatinized Starch, low-substituted hydroxypropyl cellulose, the correctives mixing of getting group component, add an amount of 5% tween 80 alcoholic solution system soft material, 30 mesh sieves are granulated, 50 ℃ of oven dry, 20 mesh sieve granulate, the adding cross-linked carboxymethyl cellulose is received, castor oil hydrogenated, mixing, tabletting promptly gets the bisulfate clopidogrel sheet.
(sheet is heavy: 250mg) in the preparation of embodiment 6 clopidogrel hydrogen sulfate dispersible tablets
Preparation method: bisulfate clopidogrel, lactose, microcrystalline Cellulose, low-substituted hydroxypropyl cellulose (interior dosage), the correctives mixing of getting group component, add the blended alcoholic solution system soft material of an amount of 3%HPMC and 5% tween 80,30 mesh sieves are granulated, 40 ℃ of oven dry, 20 mesh sieve granulate add low-substituted hydroxypropyl cellulose (outer dosage), castor oil hydrogenated, mixing, tabletting promptly gets the bisulfate clopidogrel sheet.
The dispersing uniformity of experimental example clopidogrel hydrogen sulfate dispersible tablets and dissolution in vitro test
This experimental example clopidogrel hydrogen sulfate dispersible tablets is contrast with domestic listing product clopidogrel hydrogen sulfate sheet, clopidogrel hydrogen sulfate dispersible tablets among the embodiment 1 to 6 has been carried out dispersing uniformity test and dissolution in vitro test, and its test method and result are as follows:
1, dispersing uniformity test
Experimental condition: get 2 of clopidogrel hydrogen sulfate dispersible tablets, shine dispersing uniformity inspection technique (two appendix IA of Chinese Pharmacopoeia version in 2005) in 20 ℃ ± 1 ℃ 100ml water, jolting 3 minutes, all also by No. 2 sieves, its result of the test sees the following form 1 in disintegrate:
Table 1 dispersing uniformity result of the test
Result of the test shows clopidogrel hydrogen sulfate dispersible tablets of the present invention all disintegrates and by No. 2 sieves in 3 minutes in 20 ℃ ± 1 ℃ water.
2, dissolution in vitro test
Experimental condition: shine dissolution method (two appendix XC second methods of Chinese Pharmacopoeia version in 2005) with pH2.0 buffer (potassium chloride 6.57g, adding water dissolves in right amount, add 0.1mol/L hydrochloric acid solution 119.0ml, thin up is to 1000ml again) 1000ml is solvent, rotating speed is that per minute 75 changes, operation in accordance with the law, in the time of 20 minutes, to get solution and filter in right amount, precision is measured subsequent filtrate 3.0ml, add the pH2.0 buffer and be diluted to 10ml, shake up; It is an amount of that other gets the clopidogrel hydrogen sulfate reference substance, and accurate the title decides, and adds the solution that chloride approximately pyrroles's thunder 20 μ g among every 1ml are made in above-mentioned dissolution with solvents and dilution.Get above-mentioned two kinds of solution, according to spectrophotography (two appendix IVA of Chinese Pharmacopoeia version in 2005), measure trap respectively, by the stripping quantity of every of the ratio calculation of the two trap at the wavelength place of 240nm.It the results are shown in Table 2.
Table 2 dissolution in vitro examination result
Above testing result is to as directed: clopidogrel hydrogen sulfate tablet dispersible tablet provided by the invention and commercially available common bisulfate clopidogrel compare, and this product has quick disintegrate, stripping, is uniformly dispersed, and improves advantages such as drug dissolution and bioavailability.Dispersible tablet can add after the aqueous dispersion oral, also can swallow, chew buccal, takes to carry very conveniently, and technology of the present invention is simple, can obviously reduce production costs.
Claims (6)
1, a kind of clopidogrel hydrogen sulfate dispersible tablets is characterized in that, contains percentage by weight and be 30～55% clopidogrel hydrogen sulfate, and all the other are adjuvant; Described adjuvant contains disintegrating agent, filler, lubricant, and described disintegrating agent is selected from one or both the mixture in low-substituted hydroxypropyl cellulose, the cross-linking sodium carboxymethyl cellulose, and accounting for total weight percent is 5～20%; Filler is selected from a kind of in lactose, mannitol, microcrystalline Cellulose, the pregelatinized Starch or their mixture, and accounting for total weight percent is 25～60%; Lubricant is selected from a kind of in stearic acid, castor oil hydrogenated, the micropowder silica gel or their mixture, and accounting for total weight percent is 1～5%.
2, according to the clopidogrel hydrogen sulfate dispersible tablets of claim 1, it is characterized in that containing percentage by weight and be 35～45% clopidogrel hydrogen sulfate, 55～65% adjuvant, wherein to account for total weight percent be 5～20% to disintegrating agent, it is 1～5% that lubricant accounts for total weight percent.
3, according to the clopidogrel hydrogen sulfate dispersible tablets of claim 2, it is characterized in that containing percentage by weight and be 35% clopidogrel hydrogen sulfate and 65% adjuvant, wherein to account for total weight percent be 10% to disintegrating agent, it is 1% that lubricant accounts for total weight percent.
4, the preparation method of the described clopidogrel hydrogen sulfate dispersible tablets of a kind of claim 1 adopts direct powder compression, soon tabletting behind bisulfate clopidogrel and filler, disintegrating agent, lubricant and the sweeting agent mix homogeneously.
5, the preparation method of the described clopidogrel hydrogen sulfate dispersible tablets of a kind of claim 1, adopt wet granule compression tablet, be about to bisulfate clopidogrel and filler, do not add or add part or all of disintegrating agent, sweeting agent mixes, add binding agent and make soft material, granulate 40～50 ℃ of oven dry, granulate, add in addition part or all of disintegrating agent and lubricant, tabletting behind the mix homogeneously.
6, according to the preparation method of the described clopidogrel hydrogen sulfate dispersible tablets of claim 5, it is characterized in that: used binding agent is selected from a kind of in the alcoholic solution of hydroxypropyl emthylcellulose or tween 80 or their mixture.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008102169856A CN101396350A (en) | 2008-10-29 | 2008-10-29 | Clopidogrel hydrogen sulfate dispersible tablets and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008102169856A CN101396350A (en) | 2008-10-29 | 2008-10-29 | Clopidogrel hydrogen sulfate dispersible tablets and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101396350A true CN101396350A (en) | 2009-04-01 |
Family
ID=40515351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2008102169856A Pending CN101396350A (en) | 2008-10-29 | 2008-10-29 | Clopidogrel hydrogen sulfate dispersible tablets and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101396350A (en) |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101851247A (en) * | 2010-06-04 | 2010-10-06 | 浙江华海药业股份有限公司 | Composition containing clopidogrel bisulfate crystal particles |
| CN101926756A (en) * | 2010-08-12 | 2010-12-29 | 北京赛科药业有限责任公司 | Solid preparation of clopidogrel or pharmaceutically acceptable salt thereof |
| CN102058550A (en) * | 2010-12-30 | 2011-05-18 | 江苏亚邦强生药业有限公司 | Clopidogrel bisulfate tablet and preparation method thereof |
| CN102240269A (en) * | 2010-05-12 | 2011-11-16 | 天津泰普药品科技发展有限公司 | Preparation method of crystalline clopidogrel bisulfate tablets |
| CN102302465A (en) * | 2011-08-08 | 2012-01-04 | 南京正宽医药科技有限公司 | Tablet containing clopidogrel hydrogen sulfate and preparation method thereof |
| CN102485218A (en) * | 2010-12-03 | 2012-06-06 | 丽珠医药集团股份有限公司 | Clopidogrel hydrogen sulfate tablet and preparation method thereof |
| CN103417502A (en) * | 2013-08-05 | 2013-12-04 | 青岛市中心医院 | Hydrogen sulfate clopidogrel tablet and preparation method thereof |
| CN105106165A (en) * | 2015-08-19 | 2015-12-02 | 海南科进生物制药有限公司 | Clopidogrel hydrogen sulphate tablets and preparation method thereof |
| CN105218559A (en) * | 2015-10-21 | 2016-01-06 | 云南省药物研究所 | A kind of stable non-crystalline state bisulfate clopidogrel mixture |
| CN106880608A (en) * | 2015-12-15 | 2017-06-23 | 北大方正集团有限公司 | A kind of teriflunomide dispersible tablet and preparation method thereof |
| CN109528669A (en) * | 2018-12-25 | 2019-03-29 | 哈尔滨珍宝制药有限公司 | Bisulfate clopidogrel composition, clopidogrel hydrogen sulfate tablet and preparation method thereof |
| CN114732788A (en) * | 2022-04-14 | 2022-07-12 | 浙江高跖医药科技股份有限公司 | Clopidogrel hydrogen sulfate solid preparation and preparation process thereof |
-
2008
- 2008-10-29 CN CNA2008102169856A patent/CN101396350A/en active Pending
Cited By (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102240269A (en) * | 2010-05-12 | 2011-11-16 | 天津泰普药品科技发展有限公司 | Preparation method of crystalline clopidogrel bisulfate tablets |
| CN102240269B (en) * | 2010-05-12 | 2013-04-10 | 天津泰普药品科技发展有限公司 | Preparation method of crystalline clopidogrel bisulfate tablets |
| CN101851247B (en) * | 2010-06-04 | 2013-05-29 | 浙江华海药业股份有限公司 | Composition containing clopidogrel bisulfate crystal particles |
| CN101851247A (en) * | 2010-06-04 | 2010-10-06 | 浙江华海药业股份有限公司 | Composition containing clopidogrel bisulfate crystal particles |
| CN101926756A (en) * | 2010-08-12 | 2010-12-29 | 北京赛科药业有限责任公司 | Solid preparation of clopidogrel or pharmaceutically acceptable salt thereof |
| CN101926756B (en) * | 2010-08-12 | 2012-01-18 | 北京赛科药业有限责任公司 | Solid preparation of clopidogrel or pharmaceutically acceptable salt thereof |
| CN102485218A (en) * | 2010-12-03 | 2012-06-06 | 丽珠医药集团股份有限公司 | Clopidogrel hydrogen sulfate tablet and preparation method thereof |
| CN102485218B (en) * | 2010-12-03 | 2013-05-29 | 丽珠医药集团股份有限公司 | Clopidogrel hydrogen sulfate tablet and preparation method thereof |
| CN102058550A (en) * | 2010-12-30 | 2011-05-18 | 江苏亚邦强生药业有限公司 | Clopidogrel bisulfate tablet and preparation method thereof |
| CN102058550B (en) * | 2010-12-30 | 2016-04-27 | 江苏亚邦强生药业有限公司 | Clopidogrel bisulfate tablet and preparation method thereof |
| CN102302465A (en) * | 2011-08-08 | 2012-01-04 | 南京正宽医药科技有限公司 | Tablet containing clopidogrel hydrogen sulfate and preparation method thereof |
| CN102302465B (en) * | 2011-08-08 | 2013-03-20 | 浙江昂利康制药有限公司 | Tablet containing clopidogrel hydrogen sulfate and preparation method thereof |
| CN103417502A (en) * | 2013-08-05 | 2013-12-04 | 青岛市中心医院 | Hydrogen sulfate clopidogrel tablet and preparation method thereof |
| CN105106165A (en) * | 2015-08-19 | 2015-12-02 | 海南科进生物制药有限公司 | Clopidogrel hydrogen sulphate tablets and preparation method thereof |
| CN105218559A (en) * | 2015-10-21 | 2016-01-06 | 云南省药物研究所 | A kind of stable non-crystalline state bisulfate clopidogrel mixture |
| CN106880608A (en) * | 2015-12-15 | 2017-06-23 | 北大方正集团有限公司 | A kind of teriflunomide dispersible tablet and preparation method thereof |
| CN109528669A (en) * | 2018-12-25 | 2019-03-29 | 哈尔滨珍宝制药有限公司 | Bisulfate clopidogrel composition, clopidogrel hydrogen sulfate tablet and preparation method thereof |
| CN114732788A (en) * | 2022-04-14 | 2022-07-12 | 浙江高跖医药科技股份有限公司 | Clopidogrel hydrogen sulfate solid preparation and preparation process thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101396350A (en) | Clopidogrel hydrogen sulfate dispersible tablets and preparation method thereof | |
| Bowles et al. | Co-processed excipients for dispersible tablets–part 1: Manufacturability | |
| CN101327213B (en) | Irbesartan and hydrochlorothiazide pharmaceutical composition and preparation method thereof | |
| CN101288652A (en) | Water-soluble drug sustained-release tablet and preparation method thereof | |
| CN101708336B (en) | Novel medicinal premixing auxiliary material | |
| CN102138911B (en) | Divalproex sodium sustained release tablets and preparation method thereof | |
| CN109875972B (en) | Olmesartan medoxomil and amlodipine pharmaceutical composition | |
| CN113230223A (en) | Preparation method of atorvastatin calcium film coated tablet | |
| JP2013525404A (en) | Orally disintegrating tablets containing acarbose | |
| Badshah et al. | Development of controlled-release matrix tablet of risperidone: influence of methocel®-and ethocel®-based novel polymeric blend on in vitro drug release and bioavailability | |
| CN103637994A (en) | A premix auxiliary material and a preparation technology thereof | |
| Aljaberi et al. | Tableting functionality evaluation of Prosolv Easytab in comparison to physical mixtures of its individual components | |
| Azubuike et al. | Some Pharmacopoeial and Diluent-Binder Properties of α-Cellulose derived from Maize Cob in Selected Tablet Formulations | |
| CN107669645A (en) | The preparation method of ciprofloxacin hydrocloride tablets | |
| CN102247333A (en) | Clopidogrel hydrogen sulfate tablet and preparation method thereof | |
| CN102846625A (en) | Stable valsartan, amlodipine and hydrochlorothiazide pharmaceutical composition and preparation method thereof | |
| CN102755300A (en) | Voriconazole composition and preparation method thereof | |
| Onyekweli et al. | Application of a newly developed multifunctional excipient in tablet formulation | |
| CN100425228C (en) | Dispersion tablets and its prepn. method | |
| CN102512684B (en) | Sustained release premixing agent | |
| CN109700773B (en) | Ticagrelor preparation composition and preparation method thereof | |
| Hossain et al. | Formulation development and evaluation of ticagrelor tablet for regulatory market | |
| CN102389404A (en) | Desloratadine medicament compound | |
| JPWO2004006945A1 (en) | Kampo extract-containing tablet composition and method for producing the same | |
| Nur et al. | Influence of type and content of guar gum as a disintegrant and production technique on attributes of immediate release tablets |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20090401 |